174 related articles for article (PubMed ID: 30967636)
1. JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells.
Duan L; Perez RE; Chastain PD; Mathew MT; Bijukumar DR; Maki CG
Oncogene; 2019 Jul; 38(28):5643-5657. PubMed ID: 30967636
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.
Duan L; Perez RE; Calhoun S; Maki CG
Cancer Biol Ther; 2022 Dec; 23(1):65-75. PubMed ID: 35100078
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
[TBL] [Abstract][Full Text] [Related]
4. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J
Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
6. Continual removal of H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal and early development.
Pedersen MT; Kooistra SM; Radzisheuskaya A; Laugesen A; Johansen JV; Hayward DG; Nilsson J; Agger K; Helin K
EMBO J; 2016 Jul; 35(14):1550-64. PubMed ID: 27266524
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-1 attenuates cisplatin-induced gammaH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer.
Jeon JH; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
Cancer Lett; 2008 Dec; 272(2):232-41. PubMed ID: 18762365
[TBL] [Abstract][Full Text] [Related]
8. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
[TBL] [Abstract][Full Text] [Related]
9. MHC class I chain-related molecule A and B expression is upregulated by cisplatin and associated with good prognosis in patients with non-small cell lung cancer.
Okita R; Yukawa T; Nojima Y; Maeda A; Saisho S; Shimizu K; Nakata M
Cancer Immunol Immunother; 2016 May; 65(5):499-509. PubMed ID: 26940474
[TBL] [Abstract][Full Text] [Related]
10. Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
Dalvi MP; Wang L; Zhong R; Kollipara RK; Park H; Bayo J; Yenerall P; Zhou Y; Timmons BC; Rodriguez-Canales J; Behrens C; Mino B; Villalobos P; Parra ER; Suraokar M; Pataer A; Swisher SG; Kalhor N; Bhanu NV; Garcia BA; Heymach JV; Coombes K; Xie Y; Girard L; Gazdar AF; Kittler R; Wistuba II; Minna JD; Martinez ED
Cell Rep; 2017 May; 19(8):1669-1684. PubMed ID: 28538184
[TBL] [Abstract][Full Text] [Related]
11. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
12. Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
Kuo KT; Huang WC; Bamodu OA; Lee WH; Wang CH; Hsiao M; Wang LS; Yeh CT
Clin Epigenetics; 2018 Aug; 10(1):107. PubMed ID: 30092824
[TBL] [Abstract][Full Text] [Related]
13. Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.
Ryan SL; Beard S; Barr MP; Umezawa K; Heavey S; Godwin P; Gray SG; Cormican D; Finn SP; Gately KA; Davies AM; Thompson EW; Richard DJ; O'Byrne KJ; Adams MN; Baird AM
Lung Cancer; 2019 Sep; 135():217-227. PubMed ID: 31446998
[TBL] [Abstract][Full Text] [Related]
14. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.
Gomes LR; Rocha CRR; Martins DJ; Fiore APZP; Kinker GS; Bruni-Cardoso A; Menck CFM
Cell Death Dis; 2019 Jun; 10(6):459. PubMed ID: 31189884
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment.
To KKW; Cheung KM; Cho WCS
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7217-7234. PubMed ID: 36905422
[TBL] [Abstract][Full Text] [Related]
17. Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.
Zuco V; Cassinelli G; Cossa G; Gatti L; Favini E; Tortoreto M; Cominetti D; Scanziani E; Castiglioni V; Cincinelli R; Giannini G; Zunino F; Zaffaroni N; Lanzi C; Perego P
Biochem Pharmacol; 2015 Mar; 94(2):79-90. PubMed ID: 25600908
[TBL] [Abstract][Full Text] [Related]
18. DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
Meng Y; Chen CW; Yung MMH; Sun W; Sun J; Li Z; Li J; Li Z; Zhou W; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Kai Y; Peng W; Tzatsos A; Li Y; Dai Z; Zheng W; Chan DW; Zhu W
Cancer Lett; 2018 Aug; 428():104-116. PubMed ID: 29704517
[TBL] [Abstract][Full Text] [Related]
19. Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells.
Fodor BD; Kubicek S; Yonezawa M; O'Sullivan RJ; Sengupta R; Perez-Burgos L; Opravil S; Mechtler K; Schotta G; Jenuwein T
Genes Dev; 2006 Jun; 20(12):1557-62. PubMed ID: 16738407
[TBL] [Abstract][Full Text] [Related]
20. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
